CervoMed Advances Neflamapimod with New Commercial-Ready Tablet Formulation and FDA Dose Flexibility for Dementia with Lewy Bodies
CervoMed Inc. a clinical-stage biopharmaceutical company focused on neurodegenerative disorders, announced key regulatory and pharmaceutical milestones advancing its lead investigational drug, neflamapimod, toward pivotal Phase 3...
Novo Nordisk and Hengrui Pharma Announce Exclusive Global License Agreement for Novel Oral Dual Agonist HRS-1596
Novo Nordisk A/S and Jiangsu Hengrui Pharmaceuticals Co., Ltd. announced an exclusive global license agreement for the development and commercialization of HRS-1596, an investigational once-weekly oral...
AbbVie Announces FDA Approval of JUVMO™️ for Adults with Parkinson’s Disease
Food and Drug Administration (FDA) for JUVMO™ (tavapadon) to treat adult patients living with Parkinson’s disease. JUVMO represents a first-of-its-kind therapeutic approach, utilizing a...
Sun Pharma and LIB Therapeutics Announce Global Licensing Agreement for Novel PCSK9 Inhibitor Lerodalcibep
Sun Pharmaceutical Industries Limited and LIB Therapeutics Inc. announced an exclusive global licensing, manufacturing, and commercialization agreement for lerodalcibep across international markets, excluding the United...
Empowering Pharmaceutical Innovation: Bharat Technology Wraps up a Stellar BT-PHARMACON 2k26
Bharat Technology's national conference, BT-PHARMACON 2K26, was held bringing together eminent personalities from the State Government, the Pharmacy Council of India (PCI), academia, and...
Johnson & Johnson Announces 69.2% Five-Year Overall Survival Rate for CARVYKTI in CARTITUDE-2 Study
At the five-year evaluation mark, half of the treated patients (50%) remained alive and progression-free. The trial demonstrated a notable five-year overall survival rate...